Hyperfine, Inc.
NASDAQ:HYPRMedical - Devices
+$0.22 today
- Market cap
- $51.10M
- Beta
- 1.38
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.36
Volume 1.16M
Average 0.60M
HYPR Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Hyperfine, Inc.NASDAQ: HYPR
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $515K rose 124.9% year over year, ahead of the +41.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 83.3% from the prior quarter. Over 3 fiscal years it compounded at +2.4% a year.
Context
- Depreciation & amortization amounted to 8.0% of revenue in FY2025, up 0.2 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +124.9% holds above the trailing-twelve-month pace of +41.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 1.09M USD
- Year-over-year change
- +8.0%
- 4-year CAGR
- +10.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.09M | +8.0% |
| FY2024 | 2024-12-31 | 1.01M | -4.3% |
| FY2023 | 2023-12-31 | 1.05M | +3.8% |
| FY2022 | 2022-12-31 | 1.02M | +39.8% |
| FY2021 | 2021-12-31 | 726K | — |
Depreciation & Amortization vs competitors
How HYPR compares with its peers on the latest reported figures
- HYPR's LTM Mar 2026 depreciation & amortization of $1.38M is the 3rd largest of the 7 companies compared; the peer median is $950K.
- Its year-over-year change of +41.1% is the 3rd highest of 7, against a peer median of +9.4%.
- Depreciation & amortization amounts to 9.0% of revenue for HYPR, versus a peer median of 3.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.61M | -17.9% | -18.0% | 4.4% | |
| LTM Mar 2026 | $2.15M | +48.5% | +53.1% | 3.0% | |
| LTM Mar 2026 | $1.38M | +41.1% | +2.4% | 9.0% | |
| LTM Mar 2026 | $1.2M | -11.3% | -33.9% | 1.4% | |
| FY2025 | $704K | +6.7% | -11.4% | 1100.0% | |
IMAImageneBio Inc | LTM Mar 2026 | $616K | +72.1% | -24.1% | — |
| LTM Mar 2026 | $452K | +12.2% | +3.6% | — | |
| Peer median (excluding HYPR) | $950K | +9.4% | -14.7% | 3.7% | |
Competitors are the stored peer set for HYPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (64.85M) | (73.16M) | (44.24M) | (40.72M) | (35.57M) |
| Depreciation & Amortization | 726K | 1.02M | 1.05M | 1.01M | 1.09M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.9M | 10.65M | 4.74M | 4.36M | 2.8M |
| Change in Working Capital | 8.97M | (10.93M) | (3.62M) | (3.62M) | 4.41M |
| Accounts Receivables | 981K | (1.55M) | (1.57M) | (2.77M) | 1.78M |
| Inventory | (2.67M) | (312K) | (2.21M) | 562K | (1.48M) |
| Accounts Payables | 1.44M | (1.57M) | 533K | 382K | 2.43M |
| Other Working Capital | 9.22M | (7.5M) | (365K) | (1.8M) | 1.68M |
| Other Non-Cash Items | 1.07M | 91K | 249K | 204K | (677K) |
| Operating Cash Flow | (47.18M) | (72.34M) | (41.81M) | (38.77M) | (27.95M) |
| Capital Expenditures | (2.71M) | (585K) | (804K) | (383K) | (1.19M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (2.71M) | (585K) | (804K) | (383K) | (1.19M) |
| Debt Repayment | (178K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 1.5M | 7K | 174K | 848K | 27.5M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 146.48M | 0 | 0 | 171K | 0 |
| Financing Cash Flow | 176.77M | 7K | 174K | 1.02M | 27.5M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 126.87M | (72.92M) | (42.44M) | (38.13M) | (1.63M) |
| Free Cash Flow | (49.89M) | (72.92M) | (42.61M) | (39.15M) | (29.13M) |
Hyperfine, Inc.
NASDAQ:HYPR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.